Forkhead box protein C2 (FOXC2) also known as forkhead-related protein FKHL14 (FKHL14), transcription factor FKH-14, or mesenchyme fork head protein 1 (MFH1) is a protein that in humans is encoded by the FOXC2gene.[1][2] FOXC2 is a member of the fork head box (FOX) family of transcription factors.
The protein is 501 amino acids in length. The gene has no introns; the single exon is approximately 1.5kb in size.[2][3]
FOX transcription factors are expressed during development and are associated with a number of cellular and developmental differentiation processes. FOXC2 is required during early development of the kidneys, including differentiation of podocytes and maturation of the glomerular basement membrane. It is also involved in the early development of the heart.[4]
An increased expression of FOXC2 in adipocytes can increase the amount of brown adipose tissue leading to lower weight and an increased sensitivity to insulin.[5][6]
Role in disease
Absence of FOXC2 has been shown to lead to the failure of lymphatic valves to form and problems with lymphatic remodelling. A number of mutations in the FOXC2 gene have been associated with Lymphedema–distichiasis syndrome,[7][8] It has also been suggested that there may be a link between polymorphisms in FOXC2 and varicose veins.[8][9]
↑Kaestner KH, Bleckmann SC, Monaghan AP, Schlöndorff J, Mincheva A, Lichter P, Schütz G (June 1996). "Clustered arrangement of winged helix genes fkh-6 and MFH-1: possible implications for mesoderm development". Development. 122 (6): 1751–8. PMID8674414.
↑ 2.02.1Miura N, Iida K, Kakinuma H, Yang XL, Sugiyama T (May 1997). "Isolation of the mouse (MFH-1) and human (FKHL 14) mesenchyme fork head-1 genes reveals conservation of their gene and protein structures". Genomics. 41 (3): 489–92. doi:10.1006/geno.1997.4695. PMID9169153.
↑Cederberg A, Gronning LM, Ahren B, Tasken K, Carlsson P, Enerback S (2001). "FOXC2 is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance". Cell. 106 (5): 563–73. doi:10.1016/s0092-8674(01)00474-3. PMID11551504.
↑Connell F, Brice G, Mortimer P (2008). "Phenotypic characterization of primary lymphedema". Ann. N. Y. Acad. Sci. 1131: 140–6. doi:10.1196/annals.1413.013. PMID18519967.
Fauret AL, Tuleja E, Jeunemaitre X, Vignes S (2010). "A novel missense mutation and two microrearrangements in the FOXC2 gene of three families with lymphedema-distichiasis syndrome". Lymphology. 43 (1): 14–8. PMID20552815.
Witte MH, Erickson RP, Khalil M, et al. (2009). "Lymphedema-distichiasis syndrome without FOXC2 mutation: evidence for chromosome 16 duplication upstream of FOXC2". Lymphology. 42 (4): 152–60. PMID20218083.
de Mooij YM, van den Akker NM, Bekker MN, et al. (2009). "Abnormal Shh and FOXC2 expression correlates with aberrant lymphatic development in human fetuses with increased nuchal translucency". Prenat. Diagn. 29 (9): 840–6. doi:10.1002/pd.2316. PMID19548265.
Vreeburg M, Heitink MV, Damstra RJ, et al. (2008). "Lymphedema-distichiasis syndrome: a distinct type of primary lymphedema caused by mutations in the FOXC2 gene". Int. J. Dermatol. 47 Suppl 1: 52–5. doi:10.1111/j.1365-4632.2008.03962.x. PMID18986489.
Yoshida T, Kato K, Fujimaki T, et al. (2009). "Association of a polymorphism of the apolipoprotein E gene with chronic kidney disease in Japanese individuals with metabolic syndrome". Genomics. 93 (3): 221–6. doi:10.1016/j.ygeno.2008.11.001. PMID19056482.
Ma GC, Liu CS, Chang SP, et al. (2008). "A recurrent ITGA9 missense mutation in human fetuses with severe chylothorax: possible correlation with poor response to fetal therapy". Prenat. Diagn. 28 (11): 1057–63. doi:10.1002/pd.2130. PMID18973153.
Lu Y, Dollé ME, Imholz S, et al. (2008). "Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations". J. Lipid Res. 49 (12): 2582–9. doi:10.1194/jlr.M800232-JLR200. PMID18660489.
van Steensel MA, Damstra RJ, Heitink MV, et al. (2009). "Novel missense mutations in the FOXC2 gene alter transcriptional activity". Hum. Mutat. 30 (12): E1002–9. doi:10.1002/humu.21127. PMID19760751.
Pappa KI, Gazouli M, Economou K, et al. (2010). "Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population". Gynecological Endocrinology. 27 (4): HASH(0x28c7db0). doi:10.3109/09513590.2010.490609. PMID20540670.
Joslyn G, Ravindranathan A, Brush G, et al. (2010). "Human variation in alcohol response is influenced by variation in neuronal signaling genes". Alcohol. Clin. Exp. Res. 34 (5): 800–12. doi:10.1111/j.1530-0277.2010.01152.x. PMID20201926.
Fabretto A, Shardlow A, Faletra F, et al. (2010). "A case of lymphedema-distichiasis syndrome carrying a new de novo frameshift FOXC2 mutation". Ophthalmic Genet. 31 (2): 98–100. doi:10.3109/13816811003620517. PMID20450314.
Ghalamkarpour A, Debauche C, Haan E, et al. (2009). "Sporadic in utero generalized edema caused by mutations in the lymphangiogenic genes VEGFR3 and FOXC2". J. Pediatr. 155 (1): 90–3. doi:10.1016/j.jpeds.2009.02.023. PMID19394045.
Dellinger MT, Thome K, Bernas MJ, et al. (2008). "Novel FOXC2 missense mutation identified in patient with lymphedema-distichiasis syndrome and review". Lymphology. 41 (3): 98–102. PMID19013876.
Corpeleijn E, Petersen L, Holst C, et al. (2010). "Obesity-related polymorphisms and their associations with the ability to regulate fat oxidation in obese Europeans: the NUGENOB study". Obesity (Silver Spring). 18 (7): 1369–77. doi:10.1038/oby.2009.377. PMID19876004.
Horra A, Salazar J, Ferré R, et al. (2009). "Prox-1 and FOXC2 gene expression in adipose tissue: A potential contributory role of the lymphatic system to familial combined hyperlipidaemia". Atherosclerosis. 206 (2): 343–5. doi:10.1016/j.atherosclerosis.2009.02.026. PMID19339011.